Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

A Novel Function of Nonadecanoic Acid in Regulating Glucose Homeostasis

Hou Y., Ma Y., Liu Q., Ma D., Tong Y., Xu L.

Animal Study on Type 2 Diabetes, published in Adv Sci (Weinh) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Sci (Weinh) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41738141
PMCID
PMC13159108
DOI
10.1002/advs.202509534

Abstract (original English)

Circulating odd-chain fatty acids (OCFAs), such as pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0), inversely associate with metabolic syndrome-related type 2 diabetes mellitus (T2DM), cardiovascular disease, and all-cause mortality. However, the physiological function of nonadecanoic acid (C19:0) remains unclear. In this study, we identify an inverse association between plasma C19:0 levels and T2DM in the Kazakh population in Xinjiang, China. Investigations using diet-induced obese (DIO) and db/db mouse models revealed that C19:0 has the potential to improve glucose tolerance and enhance insulin sensitivity. Mechanistically, our data demonstrate that C19:0 acts as an endogenous ligand for GPR120, mediating metabolic benefits both in vitro and in vivo. Further analyses indicate that 2-hydroxyacyl-CoA lyase (HACL1) directly participates in the biosynthesis of C19:0, with its expression regulated by peroxisome proliferator-activated receptor α (PPARα). Elevated palmitic acid (PA) levels in obesity suppress PPARα via miR548ab release, thereby impairing the PPARα-HACL1-C19:0 signaling pathway. Collectively, these findings establish a novel association between C19:0 and T2DM and elucidate a distinct mechanism accounting for reduced circulating C19:0 levels in obesity.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansMiceDiabetes Mellitus, Type 2Insulin ResistanceObesityDisease Models, AnimalGlucoseFatty AcidsPPAR alpha

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research